An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2015
At a glance
- Drugs TTP 607 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Jul 2010 Planned end date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 27 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Jan 2010 Planned initiation date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov